Evidence map›Paper›PMID 34406520›Full record

ReviewThe Journal of the Egyptian Public Health Association2021

COVID-19 clinical and laboratory diagnosis overview.

Rania A Zayed, Dalia Omran, Abeer A Zayed

Abstract readReview
In one paragraph

Review in The Journal of the Egyptian Public Health Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. COVID-19 and Diabetes: Clinical Symptoms, Acute Kidney Injury, Inflammatory Response, and Poor Prognosis Factors.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rania A ZayedClinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. rania.zayed@kasralainy.edu.eg.ORCID http://orcid.org/0000-0001-7920-7060
Dalia OmranDepartment of Endemic Medicine and Hepatogastroentrology, Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-5513-6955
Abeer A ZayedDepartment of Forensic Medicine and Toxicology, Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID https://orcid.org/0000-0003-4897-9118

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 was identified in Wuhan, China, in December 2019, and rapidly spread worldwide, being declared global pandemic on the 11th of March 2020. Since its emergence, COVID-19 has raised global concerns associated with drastic measures that were never adopted in any previous outbreak, to contain the situation as early as possible. MAIN BODY: The 2019 novel corona virus (2019-nCoV) or SARS-CoV-2 is the causative agent of COVID-19. 2019-nCoV genetic sequence was rapidly identified within few days since the first reported cases and RT-PCR kits became available for COVID-19 diagnosis. However, RT-PCR diagnosis carries a risk of false-negative results; therefore, additional serologic tests are needed. In this review, we summarize the clinical scenario that raises suspicion of COVID-19 and available laboratory diagnostics.

conclusionThe most important approach in the battle against COVID-19 is rapid diagnosis of suspicious cases, timely therapeutic intervention and isolation to avoid community spread. Diagnosis depends mainly on PCR testing and serological tests. However, even in the context of negative lab test results and clinical suspicion of COVID-19 infection, clinical decision should be based on clinical suspicion.

Indexed as

ClinicalCOVID-19LabRT-PCRSerology

Identifiers

PMID34406520
PMCPMC8371420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.